{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:47:04Z","timestamp":1791499624422,"version":"4.3.4"},"reference-count":69,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Internal Medicine, University of California Riverside School of Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Bladder cancer is a prevalent malignancy with high morbidity and mortality, particularly when diagnosed at an advanced stage. Early detection is critical, as it significantly improves prognosis and the patient\u2019s outcomes. Bladder cancer also has a high recurrence rate, necessitating long-term surveillance. While cystoscopy remains the gold standard for diagnosis and monitoring, it is invasive and costly. Urine cytology, though widely used, has high specificity for detecting high-grade urothelial carcinoma but suffers from low sensitivity and limited effectiveness as a stand-alone diagnostic tool. Urinary biomarkers offer a promising, noninvasive alternative for early detection and disease surveillance. This review examines FDA-approved urinary biomarker tests, including NMP 22, UroVysion, and BTA, highlighting their clinical utility and limitations. Additionally, we explore emerging biomarkers such as DNA methylation assays, genomic alterations, and proteomic signatures as well as advanced technologies like next-generation sequencing and machine learning-based platforms. These innovations have the potential to enhance diagnostic accuracy, risk stratification, and recurrent monitoring, ultimately improving early detection and long-term disease management. By evaluating both established and emerging urinary biomarkers, this review aims to provide clinicians and researchers with insights into evolving tools for bladder cancer diagnosis and surveillance.<\/jats:p>","DOI":"10.3390\/cancers17213425","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:59:36Z","timestamp":1761659976000},"page":"3425","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance"],"prefix":"10.3390","volume":"17","author":[{"given":"Zhenyun","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of California, Riverside, CA 92521, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyu","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of California, Riverside, CA 92521, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of California, Riverside, CA 92521, USA"},{"name":"Pathology and Laboratory Medicine Service, VA Greater Los Angeles, Los Angeles, CA 90073, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer Statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"510","article-title":"Predicting Risk of Multiple Levels of Recurrence and Progression after Initial Diagnosis of Nonmuscle-Invasive Bladder Cancer in a Multisite, Community-Based Cohort","volume":"13","author":"Garg","year":"2021","journal-title":"Cancers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1126\/science.101.2629.519","article-title":"Urine Sediment Smears as a Diagnostic Procedure in Cancers of the Urinary Tract","volume":"101","author":"Papanicolaou","year":"1945","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2005.03.014","article-title":"Urine Markers for Bladder Cancer Surveillance: A Systematic Review","volume":"47","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jama.293.7.810","article-title":"Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay","volume":"293","author":"Grossman","year":"2005","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.295.3.299","article-title":"Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay","volume":"295","author":"Grossman","year":"2006","journal-title":"JAMA"},{"key":"ref_9","first-page":"400","article-title":"Performance Characteristics of a New Monoclonal Antibody Test for Bladder Cancer: ImmunoCyt trade mark","volume":"4","author":"Fradet","year":"1997","journal-title":"Can. J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S1525-1578(10)60625-3","article-title":"The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in Urine","volume":"2","author":"Sokolova","year":"2000","journal-title":"J. Mol. Diagn."},{"key":"ref_11","first-page":"261","article-title":"Molecular Biomarkers in Bladder Cancer: A Critical Analysis","volume":"27","author":"Youssef","year":"2009","journal-title":"Urol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nm0697-621","article-title":"Detection of Bladder Cancer Recurrence by Microsatellite Analysis of Urine","volume":"3","author":"Steiner","year":"1997","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrurol.2013.89","article-title":"DNA Methylation-Based Biomarkers in Bladder Cancer","volume":"10","author":"Kandimalla","year":"2013","journal-title":"Nat. Rev. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.juro.2012.05.003","article-title":"A Multigene Urine Test for the Detection and Stratification of Bladder Cancer in Patients Presenting with Hematuria","volume":"188","author":"Sharples","year":"2012","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.juro.2016.09.118","article-title":"Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy","volume":"197","author":"Beukers","year":"2017","journal-title":"J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e32143","DOI":"10.7554\/eLife.32143","article-title":"Non-Invasive Detection of Urothelial Cancer through the Analysis of Driver Gene Mutations and Aneuploidy","volume":"7","author":"Springer","year":"2018","journal-title":"eLife"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.21037\/tau.2019.08.26","article-title":"A new era in the detection of urothelial carcinoma by sequencing cell-free DNA","volume":"8","author":"Hayashi","year":"2019","journal-title":"Transl. Androl. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Spooner, A., Moridani, M.K., Toplis, B., Chen, S., Wang, L., Zhang, Y., Li, J., Smith, R., Jones, T., and Brown, K. (2025). Benchmarking Ensemble Machine Learning Algorithms for Multi-Class, Multi-Omics Data Integration in Clinical Outcome Prediction. Brief. Bioinform., 26.","DOI":"10.1093\/bib\/bbaf116"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/1097-0142(19840401)53:7<1555::AID-CNCR2820530723>3.0.CO;2-G","article-title":"Urinary cytology and bladder cancer: The cellular features of transitional cell neoplasms","volume":"53","author":"Murphy","year":"1984","journal-title":"Cancer"},{"key":"ref_21","first-page":"412","article-title":"Urine Cytology and Adjunct Markers for Detection and Surveillance of Bladder Cancer","volume":"2","author":"Sullivan","year":"2010","journal-title":"Am. J. Transl. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/(SICI)1097-0142(19990625)87:3<118::AID-CNCR4>3.0.CO;2-N","article-title":"The accuracy of urinary cytology in daily practice","volume":"87","author":"Bastacky","year":"1999","journal-title":"Cancers"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1309\/AJCPPRZLG9KT9AXL","article-title":"Accuracy of Urine Cytology and the Significance of an Atypical Category","volume":"132","author":"Brimo","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective Analysis of Sensitivity and Specificity of Urinary Cytology and Other Urinary Biomarkers for Bladder Cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1309\/AJCPE1O9YKMRSQKG","article-title":"Accuracy and Interobserver Variability of the Cytologic Diagnosis of Low-Grade Urothelial Carcinoma in Instrumented Urinary Tract Cytology Specimens","volume":"144","author":"McCroskey","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0090-4295(02)02136-2","article-title":"Sensitivity and Specificity of Commonly Available Bladder Tumor Markers versus Cytology: Results of a Comprehensive Literature Review and Meta-Analyses","volume":"61","author":"Lotan","year":"2003","journal-title":"Urology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-5347(01)61899-8","article-title":"Comparison of Screening Methods in the Detection of Bladder Cancer","volume":"161","author":"Ramakumar","year":"1999","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0022-5347(01)65851-8","article-title":"Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical Treatment","volume":"156","author":"Soloway","year":"1996","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.urology.2005.08.064","article-title":"Bladder Tumor Markers beyond Cytology: International Consensus Panel on Bladder Tumor Markers","volume":"66","author":"Lokeshwar","year":"2005","journal-title":"Urology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/S0022-5347(05)68934-3","article-title":"Immunocyt: A new tool for detecting transitional cell cancer uzof the urinary tract","volume":"161","author":"Mian","year":"1999","journal-title":"J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/S0022-5347(05)67104-2","article-title":"A Comparison of Cytology and Fluorescence In Situ Hybridization for the Detection of Urothelial Carcinoma","volume":"164","author":"Halling","year":"2000","journal-title":"J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/S0022-5347(01)62215-8","article-title":"Cytokeratin 20: A new marker for early detection of bladder cell carcinoma","volume":"160","author":"Buchumensky","year":"1998","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/sj.neo.7900191","article-title":"Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine","volume":"3","author":"Fedriga","year":"2001","journal-title":"Neoplasia"},{"key":"ref_34","first-page":"602","article-title":"Telomerase activity in human bladder tumors and bladder washing specimens","volume":"17","author":"Wu","year":"2001","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9871","DOI":"10.1073\/pnas.91.21.9871","article-title":"Microsatellite alterations as clonal markers for the detection of human cancer","volume":"91","author":"Mao","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","first-page":"1083","article-title":"Initiation of Bladder Cancer May Involve Deletion of a Tumour Suppressor Gene on Chromosome 9","volume":"8","author":"Cairns","year":"1993","journal-title":"Oncogene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/CBM-160673","article-title":"Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes","volume":"18","author":"Borkowska","year":"2017","journal-title":"Cancer Biomark."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1158\/1078-0432.CCR-03-0127","article-title":"Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel","volume":"10","author":"Dulaimi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1158\/1055-9965.EPI-11-0067","article-title":"Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments","volume":"20","author":"Chung","year":"2011","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_40","first-page":"10271","article-title":"Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Urine of Patients with Bladder Cancer","volume":"66","author":"Hoque","year":"2006","journal-title":"Cancer Res."},{"key":"ref_41","first-page":"8659","article-title":"Aberrant Promoter Methylation Profile of Bladder Cancer and Its Relationship to Clinicopathological Features","volume":"61","author":"Maruyama","year":"2001","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ahangar, M., Kumar, R., Shariat, S.F., Siefker-Radtke, A.O., Dinney, C.P., Black, P.C., Sharma, P., Lotan, Y., Roupr\u00eat, M., and Kamat, A.M. (2024). Bladder Cancer Biomarkers: Current Approaches and Future Directions. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1453278"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Harvey, J.C., Cambridge, L.M., Ellen, C.W., Colonval, M., Hazlett, J.A., Newell, J., Zhou, X., and Guilford, P.J. (2024). Analytical validation of Cxbladder\u00ae detect, triage, and monitor: Assays for detection and management of urothelial carcinoma. Diagnostics, 14.","DOI":"10.3390\/diagnostics14182061"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Harvey, J.C., Fletcher, D., Ellen, C.W., Colonval, M., Hazlett, J.A., Zhou, X., and Newell, J.M. (2025). Analytical validation of the Cxbladder\u00ae triage plus assay for risk stratification of hematuria patients for urothelial carcinoma. Diagnostics, 15.","DOI":"10.3390\/diagnostics15141739"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"326.e1","DOI":"10.1016\/j.urolonc.2023.01.009","article-title":"Cxbladder monitor testing to reduce cystoscopy frequency in patients with bladder cancer","volume":"41","author":"Li","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"922","DOI":"10.7326\/M15-0997","article-title":"Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis","volume":"163","author":"Chou","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.juro.2016.12.096","article-title":"FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study","volume":"197","author":"Beukers","year":"2017","journal-title":"J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Charpentier, M., Gutierrez, C., Guillaudeux, T., Verhoest, G., and Pedeux, R. (2021). Noninvasive urine-based tests to diagnose or detect recurrence of bladder cancer. Cancers, 13.","DOI":"10.3390\/cancers13071650"},{"key":"ref_49","first-page":"786","article-title":"Urine-Based Mutation and Methylation Panel for Bladder Cancer Detection","volume":"22","author":"Xu","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3233\/CBM-160261","article-title":"Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer","volume":"18","author":"Fantony","year":"2017","journal-title":"Cancer Biomark."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13148-016-0303-5","article-title":"UroMark-a urinary biomarker assay for the detection of bladder cancer","volume":"9","author":"Feber","year":"2017","journal-title":"Clin. Epigenet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2009.07.041","article-title":"Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples","volume":"58","author":"Renard","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"387.e1","DOI":"10.1016\/j.urolonc.2015.04.014","article-title":"Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer","volume":"33","author":"Fantony","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the Bladder EpiCheck\u2122 methylation test for patients under surveillance for non-muscle-invasive bladder cancer: Results of a multicenter, prospective, blinded clinical trial","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur. Urol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.euf.2024.05.024","article-title":"Diagnostic test accuracy of urinary DNA methylation-based biomarkers for the detection of primary and recurrent bladder cancer: A systematic review and meta-analysis","volume":"10","author":"Carvalho","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/jclinpath-2018-205393","article-title":"Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer","volume":"72","author":"Pycha","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3892\/mco.2021.2415","article-title":"Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: A pilot study","volume":"15","author":"Jain","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/iju.15338","article-title":"Urinary Markers for Bladder Cancer Diagnosis: A Review of Current Status and Future Challenges","volume":"31","author":"Tomiyama","year":"2024","journal-title":"Int. J. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lee, N., Canagasingham, A., Bajaj, M., Shanmugasundaram, R., Hutton, A., Bucci, J., Graham, P., Thompson, J., and Ni, J. (2022). Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: From functional roles to clinical significance. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1019391"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"40832","DOI":"10.18632\/oncotarget.16586","article-title":"Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer","volume":"8","author":"Du","year":"2017","journal-title":"Oncotarget"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/kjm2.12845","article-title":"The value of urinary exosomal microRNA-21 in the early diagnosis and prognosis of bladder cancer","volume":"40","author":"Yang","year":"2024","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Demir, R., Koc, S., Ozturk, D.G., Bilir, S., Ozata, H.I., Williams, R., Christy, J., Akkoc, Y., Tinay, I., and Gunduz-Demir, C. (2024). Artificial intelligence assisted patient blood and urine droplet pattern analysis for non-invasive and accurate diagnosis of bladder cancer. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-52728-7"},{"key":"ref_63","unstructured":"Yu, J., Xie, M., Wang, Y., Fu, T., Xu, X., and Wang, J. (2025). Bladder cancer diagnosis with deep learning: A multi-task framework and online platform. arXiv."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tsuneki, M., Abe, M., and Kanavati, F. (2023). Deep learning-based screening of urothelial carcinoma in whole slide images of liquid-based cytology urine specimens. Cancers, 15.","DOI":"10.20944\/preprints202211.0249.v1"},{"key":"ref_65","unstructured":"Abbas, S., Soomro, N., Shafik, R., Heer, R., and Adhikari, K. (2025). AI-Based Clinical Rule Discovery for NMIBC Recurrence through Tsetlin Machines. arXiv."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Liosis, K.C., Marouf, A.A., Rokne, J.G., Ghosh, S., Bismar, T.A., and Alhajj, R. (2023). Genomic Biomarker Discovery in Disease Progression and Therapy Response in Bladder Cancer Utilizing Machine Learning. Cancers, 15.","DOI":"10.3390\/cancers15194801"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Dimitrov, G., Mangaldzhiev, N., Slavov, C., and Popov, E. (2024). Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review. Cancers, 16.","DOI":"10.3390\/cancers16173056"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ferro, M., Falagario, U.G., Barone, B., Maggi, M., Crocetto, F., Busetto, G.M., Giudice, F.D., Terracciano, D., Lucarelli, G., and Lasorsa, F. (2023). Artificial intelligence in the advanced diagnosis of bladder cancer\u2014Comprehensive literature review and future advancement. Diagnostics, 13.","DOI":"10.3390\/diagnostics13132308"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jmoldx.2024.04.001","article-title":"EarlyTect BCD, a streamlined PENK methylation test in urine DNA, effectively detects bladder cancer in patients with hematuria","volume":"26","author":"Bang","year":"2024","journal-title":"J. Mol. Diagn."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3425\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:35:22Z","timestamp":1761705322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":69,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213425"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213425","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]}}}